MHRA kicks off new ac­cel­er­at­ed drug ap­proval path­way with ‘in­no­va­tion pass­ports’

As the UK no longer par­tic­i­pates in the Eu­ro­pean Med­i­cines Agency, the coun­try’s drug reg­u­la­tor is get­ting cre­ative in try­ing to at­tract top bio­phar­ma com­pa­nies to sub­mit ap­pli­ca­tions to the EU and UK sep­a­rate­ly.

As part of this cre­ative push, the UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency (MHRA), the UK’s stand­alone med­i­cines and med­ical de­vices reg­u­la­tor, last week un­veiled a new ac­cel­er­at­ed drug ap­proval path­way, known as the In­no­v­a­tive Li­cens­ing and Ac­cess Path­way (ILAP).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.